Fujita Yuji, Koeda Atsuhiko, Fujino Yasuhisa, Onodera Makoto, Kikuchi Satoshi, Niitsu Hisae, Iwasaki Yasumasa, Usui Kiyotaka, Inoue Yoshihiro
Department of Emergency Medicine Iwate Medical University School of Medicine Morioka Iwate Japan.
Poisoning and Drug Laboratory Division Critical Care and Emergency Center Iwate Medical University Hospital Morioka Iwate Japan.
Acute Med Surg. 2015 Dec 28;3(3):230-236. doi: 10.1002/ams2.182. eCollection 2016 Jul.
Reporting of the analytical and clinical findings of synthetic cannabinoids and cathinones is essential in carrying out a complete clinical assessment of new psychoactive substances.
From 2012 to 2014, we examined synthetic cathinone and cannabinoid poisoning in six patients aged 22-42 years old. Analyses of these compounds were carried out using liquid chromatography-tandem mass spectrometry.
The observed clinical symptoms were similar to those reported for intoxication with synthetic cathinones and cannabinoids. In cases of intoxication with synthetic cathinones, the psychiatric and neurological symptoms were long-lasting, and these compounds were detected in serum for 15-48 h after use. Although the clinical symptoms induced by the synthetic cannabinoids disappeared within several hours after use, the range of serum concentrations of these compounds was ≤5 ng/mL for 1-3 h after use. In one fatal case, in which high serum concentrations of synthetic cathinones and cannabinoids were detected, the most plausible cause of death was heart failure due to overdose with these drugs. The long-lasting symptoms induced by synthetic cathinones correlated with the long detection window in serum, whereas the early disappearance of symptoms induced by synthetic cannabinoids corresponded to the short detection window in serum.
This study shows that the profiles of synthetic cathinones and cannabinoids in serum are closely related to the duration of the toxic symptoms and that concomitant use of two psychoactive drugs with different pharmacological actions may have the potential for fatal cardiotoxicity.
报告合成大麻素和卡西酮的分析及临床研究结果对于全面临床评估新型精神活性物质至关重要。
2012年至2014年,我们对6名年龄在22至42岁之间的合成卡西酮和大麻素中毒患者进行了检查。使用液相色谱 - 串联质谱法对这些化合物进行分析。
观察到的临床症状与合成卡西酮和大麻素中毒报告的症状相似。在合成卡西酮中毒病例中,精神和神经症状持续时间长,使用后15至48小时在血清中检测到这些化合物。虽然合成大麻素引起的临床症状在使用后数小时内消失,但使用后1至3小时这些化合物的血清浓度范围≤5 ng/mL。在一例致命病例中,检测到血清中合成卡西酮和大麻素浓度很高,最可能的死因是这些药物过量导致的心力衰竭。合成卡西酮引起的持久症状与血清中较长的检测窗口期相关,而合成大麻素引起的症状早期消失与血清中较短的检测窗口期相对应。
本研究表明,血清中合成卡西酮和大麻素的情况与中毒症状持续时间密切相关,同时使用两种具有不同药理作用的精神活性药物可能具有致命心脏毒性的风险。